{"protocolSection":{"identificationModule":{"nctId":"NCT06471231","orgStudyIdInfo":{"id":"23171 - EVSS"},"organization":{"fullName":"Azienda Usl di Bologna","class":"OTHER_GOV"},"briefTitle":"Renal Outcomes in the Early Use of Vasopressin in the Treatment of Septic Shock","officialTitle":"Renal Outcomes in the Early Use of Vasopressin in the Treatment of Septic Shock","acronym":"EVSS"},"statusModule":{"statusVerifiedDate":"2024-05","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-05-15","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-05-15","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-05-15","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-05-14","studyFirstSubmitQcDate":"2024-06-17","studyFirstPostDateStruct":{"date":"2024-06-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-17","lastUpdatePostDateStruct":{"date":"2024-06-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Azienda Usl di Bologna","class":"OTHER_GOV"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The aim of the present study is to verify whether the earlier association of vasopressin and norepinephrine, in patients in septic shock, determines variations in terms of use of renal function replacement techniques in the first 7 days of hospitalization in Intensive Care, compared to patients in whom vasopressin is added only when norepinephrine reaches a higher dose.","detailedDescription":"The aim of the present study is to verify whether the earlier association of vasopressin and norepinephrine, in patients in septic shock, determines variations in terms of use of renal function replacement techniques in the first 7 days of hospitalization in Intensive Care, compared to patients in whom vasopressin is added only when norepinephrine reaches a higher dose. The study is aimed at patients admitted to the ICU with a diagnosis of septic shock on admission or in the first 24 hours of admission.\n\nPatients will be divided and randomized in a 1:1 ratio through a computer-generated scheme, when the dose of norepinephrine administered is ≥ 0.25 mcg/kg/min, into the following groups:\n\n* Group A: when the norepinephrine dosage is equal to or greater than 0.25 mcg/kg/min in the absence of adequate MAP (Mean arterial pressure \\>65 mmhg), vasopressin infusion will be associated with the standard dosage of 0.3UI/min.\n* Group B (control): the infusion of vasopressin at a dosage of 0.3 IU/min will be associated if norepinephrine exceeds the dosage of 0.5 mcg/kg/min in the absence of adequate MAP."},"conditionsModule":{"conditions":["Septic Shock","Renal Function Replacement"],"keywords":["vasopressin","norepinephrine","renal function replacement","Septic Shock"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"Patients will be divided and randomized in a 1:1 ratio through a computer-generated scheme, when the dose of norepinephrine administered is ≥ 0.25 mcg/kg/min, into the following groups:\n\n* Group A: when the norepinephrine dosage is equal to or greater than 0.25 mcg/kg/min in the absence of adequate MAP (Mean arterial pressure \\>65 mmhg), vasopressin infusion will be associated with the standard dosage of 0.3UI/min.\n* Group B (control): the infusion of vasopressin at a dosage of 0.3 IU/min will be associated if norepinephrine exceeds the dosage of 0.5 mcg/kg/min in the absence of adequate MAP.","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"SINGLE","maskingDescription":"An expert nephrology consultant has been included among the investigators to assess the need for CRRT according to KDIGO criteria, and he will be blinded to the subject allocation. In addition, the physicians who will perform ultrasound evaluation will be blinded to the subject allocation, in order to reduce the potential bias of overestimating the efficacy of the study treatment.","whoMasked":["INVESTIGATOR"]}},"enrollmentInfo":{"count":264,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Group A","type":"EXPERIMENTAL","description":"Group A: when the norepinephrine dosage is equal to or greater than 0.25 mcg/kg/min in the absence of adequate MAP (Mean arterial pressure \\>65 mmhg), vasopressin infusion will be associated with the standard dosage of 0.3UI/min.","interventionNames":["Drug: vasopressin infusion when the norepinephrine dosage is equal to or greater than 0.25 mcg/kg/min"]},{"label":"Group B","type":"ACTIVE_COMPARATOR","description":"Group B (control): the infusion of vasopressin at a dosage of 0.3 IU/min will be associated if norepinephrine exceeds the dosage of 0.5 mcg/kg/min in the absence of adequate MAP.","interventionNames":["Drug: vasopressin infusion when the norepinephrine dosage is equal to or greater than 0.5 mcg/kg/min"]}],"interventions":[{"type":"DRUG","name":"vasopressin infusion when the norepinephrine dosage is equal to or greater than 0.25 mcg/kg/min","description":"when the norepinephrine dosage is equal to or greater than 0.25 mcg/kg/min in the absence of adequate MAP (Mean arterial pressure \\>65 mmhg), vasopressin infusion will be associated with the standard dosage of 0.3UI/min.","armGroupLabels":["Group A"]},{"type":"DRUG","name":"vasopressin infusion when the norepinephrine dosage is equal to or greater than 0.5 mcg/kg/min","description":"the infusion of vasopressin at a dosage of 0.3 IU/min will be associated if norepinephrine exceeds the dosage of 0.5 mcg/kg/min in the absence of adequate MAP","armGroupLabels":["Group B"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"30% or more reduction in terms of the use of renal function replacement","description":"The primary objective of the study is to verify whether the earlier association of vasopressin and norepinephrine determines a 30% or more reduction in terms of the use of renal function replacement techniques in the first 7 days of hospitalization in the Intensive Care Unit (ICU), compared to patients in whom the vasopressin is added only when norepinephrine reaches a higher dosage.","timeFrame":"7 days"}],"secondaryOutcomes":[{"measure":"early association of vasopressin improves renal function","description":"To assess the protective effect of early vasopressin association, the Kidigo score will be calculated for every subject at enrollment time, and daily, for 7 days. The maximum value and the greatest increase will be evaluated and compared between study and control group","timeFrame":"7 days"},{"measure":"rly addition of vasopressin modifies renal perfusion","description":"verify whether the early addition of vasopressin modifies renal perfusion assessed ultrasoundally according to the CEUS method;","timeFrame":"7 days"},{"measure":"addition of vasopressin modifies the fluid balance of patients","description":"To assess the impact of early vasopressin association on the total amount of fluids administrated in the resuscitative phase of septic shock treatment, the fluid balance at 48 hours and 72 hours since ICU admission will be calculated for every subject, and compared between study and control group.","timeFrame":"48 and 72 hours"},{"measure":"early combined treatment with vasopressin reduces the duration of the need for CRRT","description":"verify whether early combined treatment with vasopressin reduces the duration of the need for CRRT (Continuous Renal Replacement Therapy) in patients who require such support during hospitalization in the ICU","timeFrame":"7 days"},{"measure":"early association of vasopressin reduces the onset of supraventricular arrhythmias","description":"verify whether the early association of vasopressin reduces the onset of supraventricular arrhythmias (atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia) during treatment with vasopressor drugs","timeFrame":"7 days"},{"measure":"intestinal and/or digital and/or limb ischemia;","description":"The incidence of intestinal and/or digital and/or limb ischemia during the study period (7 days since enrollment) will be evaluated and compared between study and control group.","timeFrame":"7 days since enrollment"},{"measure":"Length of stay in ICU","description":"Length of stay in ICU (days) will be compared between study and control group","timeFrame":"28 and 90 days"},{"measure":"Mortality","description":"Mortality at 28 and 90 days will be evaluated for every subject and between study and control group","timeFrame":"28 and 90 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* patients suffering from septic shock hospitalized in an intensive setting\n* patients over 18 years and under 80 years of age\n* patients within 24 hours of clinical diagnosis, and requiring, in this time window, a norepinephrine dosage equal to or greater than 0.25 mcg/kg/min according to the patient's ideal weight (IBW)\n* patients capable of expressing informed consent to treatment.\n\nExclusion Criteria:\n\n* patients in the absence of consent to participate in the study and to the processing of personal and particular data;\n* patients under 18 years of age or over 80 years of age;\n* patients who died within the first 24 hours of admission to the ICU;\n* patients requiring a norepinephrine dosage lower than 0.25 mcg/kg/min in the first 24 hours of hospitalization in the ICU;\n* patients with recent acute coronary syndrome (within the previous 7 days);\n* patients with allergy/intolerance to the drugs used in the study or to any component of the study drug including excipients;\n* pregnant patients;\n* breastfeeding individuals;\n* patients who need to start renal replacement treatment within 24 hours of admission to the ICU for dialysis emergencies that cannot be deferred;\n* patients with a history of end-stage renal failure or already undergoing dialysis treatment (CKD stages 4 and 5, with glomerular filtration \\< 30 ml/min);\n* single kidney patients;\n* patients with bilateral renal hypoplasia;\n* patients undergoing kidney transplant;\n* patients undergoing haemoperfusion with an adsorbent cartridge for bacterial endotoxin.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Lorenzo Giuntoli, Md","role":"CONTACT","phone":"0516478868","email":"lorenzo.giuntoli@ausl.bologna.it"}],"locations":[{"facility":"Azienda Unità Sanitaria Locale","status":"RECRUITING","city":"Bologna","zip":"40100","country":"Italy","contacts":[{"name":"Lorenzo Giuntoli, Md","role":"CONTACT","phone":"0516478868","email":"lorenzo.giuntoli@ausl.bologna.it"},{"name":"Lorenzo Giuntoli, Md","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":44.49381,"lon":11.33875}}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000012772","term":"Shock, Septic"},{"id":"D000012769","term":"Shock"}],"ancestors":[{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000018805","term":"Sepsis"},{"id":"D000007239","term":"Infections"},{"id":"D000018746","term":"Systemic Inflammatory Response Syndrome"},{"id":"D000007249","term":"Inflammation"}],"browseLeaves":[{"id":"M15577","name":"Shock","asFound":"Shock","relevance":"HIGH"},{"id":"M15580","name":"Shock, Septic","asFound":"Septic Shock","relevance":"HIGH"},{"id":"M20864","name":"Sepsis","relevance":"LOW"},{"id":"M16869","name":"Toxemia","relevance":"LOW"},{"id":"M10283","name":"Infections","relevance":"LOW"},{"id":"M6368","name":"Communicable Diseases","relevance":"LOW"},{"id":"M16355","name":"Syndrome","relevance":"LOW"},{"id":"M20818","name":"Systemic Inflammatory Response Syndrome","relevance":"LOW"},{"id":"M10293","name":"Inflammation","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC01","name":"Infections"}]},"interventionBrowseModule":{"meshes":[{"id":"D000014667","term":"Vasopressins"},{"id":"D000001127","term":"Arginine Vasopressin"},{"id":"D000009638","term":"Norepinephrine"}],"ancestors":[{"id":"D000000316","term":"Adrenergic alpha-Agonists"},{"id":"D000000322","term":"Adrenergic Agonists"},{"id":"D000018663","term":"Adrenergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000013566","term":"Sympathomimetics"},{"id":"D000001337","term":"Autonomic Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000014662","term":"Vasoconstrictor Agents"},{"id":"D000006490","term":"Hemostatics"},{"id":"D000003029","term":"Coagulants"},{"id":"D000050034","term":"Antidiuretic Agents"},{"id":"D000045283","term":"Natriuretic Agents"}],"browseLeaves":[{"id":"M17414","name":"Vasopressins","asFound":"Commonly","relevance":"HIGH"},{"id":"M4437","name":"Arginine Vasopressin","asFound":"Commonly","relevance":"HIGH"},{"id":"M12575","name":"Norepinephrine","asFound":"Cesarean Section","relevance":"HIGH"},{"id":"M20746","name":"Adrenergic Agents","relevance":"LOW"},{"id":"M3668","name":"Adrenergic alpha-Agonists","relevance":"LOW"},{"id":"M3673","name":"Adrenergic Agonists","relevance":"LOW"},{"id":"M20504","name":"Neurotransmitter Agents","relevance":"LOW"},{"id":"M16345","name":"Sympathomimetics","relevance":"LOW"},{"id":"M17409","name":"Vasoconstrictor Agents","relevance":"LOW"},{"id":"M9576","name":"Hemostatics","relevance":"LOW"},{"id":"M6259","name":"Coagulants","relevance":"LOW"},{"id":"T1","name":"Arginine","relevance":"LOW"}],"browseBranches":[{"abbrev":"NaAg","name":"Natriuretic Agents"},{"abbrev":"VaCoAg","name":"Vasoconstrictor Agents"},{"abbrev":"Coag","name":"Coagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}